



GOVERNMENT OF THE DISTRICT OF COLUMBIA



899 North Capitol St. NE – 2nd Floor
Washington, DC 20002
February 28, 2018
8:30 am – 10:30 am

BOARD OF MEDICINE

OPEN SESSION AGENDA

Mission Statement:

“To **protect** and enhance the health, safety, and well-being of District of Columbia residents by **promoting** evidence-based best practices in health regulation, high standards of quality care and implementing policies that **prevent** adverse events.”

BOARD MEETING PARTICIPANTS:

BOARD MEMBERS:	
Andrea Anderson, MD (AA)	
Preetha Iyengar, MD (PI)	
Lawrence Manning, MD (LM)	
Thomas Dawson, Esq. (TD)	
Jeffrey Smith, MD (JS)	
Terrence Straub (TS)	
Archie Rich (AR)	
Vikisha Fripp, MD (VF)	
David Wessel, MD (DW)	
Thomas Smith (TS2)	
Joshua Wind, MD (JW)	
BOARD STAFF:	
Frank Meyers, JD – Executive Director	
Lisa Robinson – Health Licensing Specialist	
Mary Harris – Health Licensing Specialist	
Aisha Nixon – Health Licensing Specialist	
Angela Braxton – Health Licensing Specialist	
Emilia Moran – Investigator	
Diane Moorer – IT Support	
LEGAL STAFF:	
Suzanne Fenzel, Esq. – Board Attorney Advisor	
Ajay Gohil, Esq. – Board Attorney Advisor	

The agenda begins on the next page with the ‘Call to Order’.¹

¹ The order in which the following agenda items are listed does not necessarily reflect the order in which the items will be discussed during the meeting.

OPEN SESSION

CALL TO ORDER		
OS-18-02-001 ALL	<u>INTRODUCTIONS</u> A. BOARD MEMBERS B. BOARD STAFF	
APPROVAL OF MINUTES, CONSENT AGENDA AND STAFF REPORTS		
OS-18-02-002 ALL	<u>BOARD/DEPARTMENT REPORT</u> A. BOARD CHAIR'S REPORT B. EXECUTIVE DIRECTOR'S REPORT i. Upcoming MTL Renewals The Executive Director will provide an update on the upcoming MTL renewals, including a recent meeting with the GME programs as well as potential future changes to training licensure requirements. ii. Board Email Addresses The Mayors Office of Talent and Appointment (MOTA) will be reaching out to each board member to assist in setting up their DC.gov email address. iii. Dr. Orlowski Award Recipient Staff was recently notified that the prior board chair, Dr. Janis Orlowski, has been selected by FSMB for the 2018 John H. Clark, MD Leadership Award. This award will be given at the 2018 FSMB Annual Meeting in Charlotte, North Carolina. iv. Licensure Census The Executive Director will provide an update on the current licensure census in the District. C. BOARD ATTORNEY'S REPORT	
OS-18-02-003 ALL	<u>OPEN SESSION MINUTES</u> Board Action: Consideration of the Open Session minutes from the January 31, 2017 meeting. Background: The Open Session Minutes are a record of the Board's past meeting(s), describing the events, list of attendees, a statement of the issues considered and related responses or decisions of the Board.	

OS-18-02-004 ALL	<p><u>OPEN CONSENT AGENDA</u></p> <p>Board Action: Consideration of the current February 28, 2018, Open Consent Agenda items for purposes of review and/or ratification of Board actions taken since the last Board meeting.</p> <p>Background: The Open Consent Agenda is a record of the decisions and/or actions taken by the Board or its staff since the last meeting of the Board.</p>	
---------------------	---	--

The Open Session Agenda continues on the next page with ‘Misc. Items for Discussion’.

MISC. ITEMS FOR DISCUSSION

OS-18-02-005 ALL	<p><u>OVERVIEW OF BOARD POWER AND DUTIES</u></p> <p>Board Action: To review the presentation from the Board legal counsel regarding Board powers and duties.</p> <p>Background: With the recent changes in Board membership, staff felt it would be beneficial to provide a brief overview of the power and duties of the Board.</p>	SF
OS-18-02-006 ALL	<p><u>COLLABORATIVE PRACTICE REGULATIONS</u></p> <p>Board Action: To review the comments received on the Collaborative Practice Regulations, which were drafted jointly with the Board of Medicine pursuant to DC Official Code § 3-1202.08(h)(2).</p> <p>Background: DC Official Code § 3-1202.08(h)(2) states that the Board of Pharmacy and the Board of Medicine shall jointly develop and issue regulations governing the implementation and use of collaborative practice agreements between a licensed pharmacist and a licensed physician covering the following:</p> <ol style="list-style-type: none">1. Specification of the drug therapy to be provided and any tests that may be necessarily incident to its provision;2. The conditions for initiating, modifying, or discontinuing a drug therapy; and3. Directions concerning the monitoring of a drug therapy, including the conditions that would warrant a modification to the dose, dosage regime, or dosage form of the drug therapy; and4. Establish policies and procedures for approving, disapproving, and revoking collaborative practice agreements. <p>The Board of Pharmacy previously drafted and then published for comment regulations governing collaborative practice. A first set of comments were received, which led to modifications to the regulations based on feedback. The Board of Medicine previously reviewed these changes, and approved the updated regulations.</p> <p>The updated regulations were then published again for comment, which have been received. The Board of Pharmacy has completed their review of the comments, and believes no further modifications are necessary. As such, this information is being provided to the Board of Medicine for review to determine if the current version of the regulations needs any further modification, or can be enacted as is.</p> <p>A copy of the most recent draft of the collaborative practice regulations and related comments are being provided for the Board's review and guidance.</p>	FM

<p>OS-18-02-007 ALL</p>	<p><u>REQUEST FOR APPROVAL OF NON-ACGME FELLOWSHIP PROGRAM</u></p> <p>Board Action: To review the request for approval, and supplemental documents, submitted by Children’s National Medical Center (CNMC) regarding their non-ACGME accredited Pediatric Cardiac Anesthesiology Fellowship training program.</p> <p>Background: Pursuant to 17 DCMR § 4611.2(c), applicants for an MTL II license must be participating in an ACGME, AOA or Board approved postgraduate clinical training fellowship program. Staff recently received a request from WHC for approval of their Stroke/Vascular Neurology Internship program.</p>	
<p>OS-18-02-008 ALL</p>	<p><u>REQUEST FOR APPROVAL OF NON-ACGME FELLOWSHIP PROGRAM</u></p> <p>Board Action: To review the request for approval, and supplemental documents, submitted by George Washington University Hospital (GWUH) regarding their ACGME accredited Neuro-Radiology Fellowship training program.</p> <p>Of note, GWUH’s program is ACGME accredited, however it’s accreditation is for only one (1) year, which is about to expire, and therefore Board approval is necessary to grant any future licenses.</p> <p>Background: Pursuant to 17 DCMR § 4611.2(c), applicants for an MTL II license must be participating in an ACGME, AOA or Board approved postgraduate clinical training fellowship program. Staff recently received a request from GW for approval of their Neuro-Radiology Fellowship training program.</p>	
<p>OS-18-02-009 ALL</p>	<p><u>2018 FSMB ANNUAL MEETING</u></p> <p>Board Action: To determine who will represent the District of Columbia Board of Medicine at the 2018 FSMB Annual Meeting.</p> <p>Background: The 2018 FSMB Annual Meeting is scheduled to take place from April 26 to April 28th in Charlotte, North Carolina. Due to Mayoral Order 2016-040, travel to North Carolina on behalf of the District of Columbia government is prohibited. As the District is not the only jurisdiction prohibited from traveling to North Carolina, the FSMB has made arrangements for Board delegates to have remote access to the House of Delegates Annual Business Meeting, including the ability to vote.</p>	

	To accomplish this, the Board will need to nominate a voting delegate, and alternate delegate, who will then be trained on the use of the remote access technology.	
--	---	--

End of Open Session.

TO BE READ BY BOARD CHAIR:

This concludes the Public Open Session of the meeting and pursuant to DC Official Code § 2-575(b), the Board will now move into the Closed Executive Session portion of the meeting to discuss the following:

- 1. To consult with an attorney to obtain legal advice and to preserve the attorney-client privilege between an attorney and a public body, or to approve settlement agreements pursuant to § 2-575(b)(4)(a);**
- 2. Preparation, administration, or grading of scholastic, licensing, or qualifying examinations pursuant to section § 2-575(b)(6);**
- 3. To discuss disciplinary matters pursuant to section § 2-575(b)(9);**
- 4. To plan, discuss, or hear reports concerning ongoing or planned investigation of alleged criminal or civil misconduct or violations of law or regulations, if disclosure to the public would harm the investigation pursuant to section § 2-575(b) (14).**

Based on the forgoing, is there a motion to go into Closed Executive Session?